| An oligosaccharide anthracycline antineoplastic antibiotic isolated form the bacterium streptomyces galilaeus. Aclarubicin intercalates into DNA and inhibits both the topoisomerase I and II enzymes, thereby inhibiting dna replication and ultimately, interfering with RNA and protein synthesis. Aclarubicin has been shown, in vitro, to be antagonistic with agents that inhibit topoisomerase II, such as etoposide, teniposide and amsacrine. This agent appears to be associated with less cardiotoxicity compared to other agents within the anthracycline class. Aclarubicin is from the group Aclacinomycin Antibiotic
Other Names for Aclarubicin
Aclarubicin
1-naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5, 7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-((2R-trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl) -.alpha.-L-lyxo-hexopyranosyl]-3-(dimethylamino)-.alpha.-L-lyxo-hexopyranosyl]oxy]-, methyl ester,(1R-(1.alpha.,2.beta.,4.beta.))-(9CI)
ACM-A
Aclacin
Aclacinomycin
Aclacinomycin A
Aclacinomycin A hydrochloride
Aclacinomycin-A
Aclacinomycine
Aclacinon
Aclaplastin
Aclarubicin Hydrochloride
Antibiotic MA144-A1
Jaclacin
MA144-A1
NSC 208734
[1R-(1alpha,2beta,4beta)]-2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-[(2R-trans)-tetrahydeo-6-methyl-5-oxo-2H-pyran-2-yl]-alpha-L-lyxo-hexopyranosyl]-3-(dimethylamino-alpha-L-lyxo-hexopyranosyl)oxy]-
[1R-(1alpha,2beta,4beta)]-2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-[(2R-trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl]-alpha-L-lyxo-hexopyranosyl]-3-(dimethylamino-alpha-L-lyxo-hexopyranosyl)oxy]-1-naphthacenecarboxylic acid methyl ester
Source NCI Thesaurus License
|
Medical Dictionary 
